|Description||ELND006 is one of the newest molecules to be reported on regarding the testing of the β-amyloid hypothesis. At the 2010 Alzheimer’s Association International Conference on Alzheimer’s Disease in which ELND006 was reported to have an in vitro IC50 = 0.34 nM against APP and IC50 = 5.3 nM versus Notch signaling.|
|Brife Description||A novel oral γ-secretase inhibitor|
|Appearance||White solid powder|
|Synonyms||(4R)-4-cyclopropyl-7,8-difluoro-5-[4-(trifluoromethyl)phenyl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline; UNII-7F5QGV49GL; ELND006; ELND-006; 959997-22-9; (R)-4-Cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo(4,3-c)quinoline; (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline; 7F5QGV49GL; SCHEMBL486044; GTPL7337; CHEMBL2396778|
|Solubility||Soluble in DMSO, not in water|
|Storage||Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -48℃ for long term (months to years).|
|Current Developer||Elan Pharmaceuticals|
Semagacestat is an inhibitor of the γ-secretase complex that blocks the production of Aβ38 (IC50= 12.0 nM), Aβ40 (IC50= 12.1 nM), and Aβ42 (IC50= 10.9 nM) fro...
BMS-708163, also called Avagacestat, is a potent, orally bioavailable inhibitor of γ-secretase that more potently inhibits the cleavage of APP (IC50s = 0.30 nM)...
MK 0752, a potent, reversible inhibitor of γ-secretase (IC50 ~50 nM), reduces the cleavage of APP to Aβ40 in human neuroblastoma SH-SY5Y cells (IC50= 5 nM).
BMS 299897, under the IUPAC name 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, synthesized by the radiosynth...
DAPT, also called γ-Secretase Inhibitor IX, is a potent and selective inhibitor of γ-secretase which leads to a reduction in Aβ40 and Aβ42 levels in human prima...
GSI-136 is an amyloid precursor protein secretase inhibitor.
Flurizan, also called Tarenflurbil, is a nonsteroidal anti-inflammatory drug which inhibits γ-secretase activity leading to preventing the formation of the amyl...
PF 3084014 hydrobromide, developed by Pfizer, is a potent γ-secretase inhibitor (in whole cell: IC50= 1.2 nM; in cell-free assaysand IC50= 6.2 nM).
MRK 560, under the IUPAC name N-((1r,4r)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)-1,1,1-trifluoromethanesulfonamide, is a novel orally bio...
CHF5074, also known as CSP-1103, is a novel γ-secretase modulator. It could reduce Aβ42 and Aβ40 secretion, which IC50 value is 3.6 and 18.4 μM respectively. It...
BMS-433796 is a γ-secretase inhibitor. Chronic dosing of BMS-433796 in Tg2576 mice suggested a narrow therapeutic window and Notch-mediated toxicity at higher d...
gamma-secretase modulator 2
gamma-secretase modulator 2，a triazole derivative, a potent and selective γ-secretase modulator so as to selectively attenuate production of Aβ(1-42) and hence ...
LY-411575 isomer 1
LY-411575 isomer 1, is an isomer of LY411575, which is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-based...
Compound W, also called 3,5-bis(4-Nitrophenoxy)benzoic acid, a 3,3'-diiodothyronine sulfate cross-reactive substance, is an inhibitor of γ-secretase which cause...
MK-0752 sodium salt
MK-0752 sodium salt is a novel potent γ-secretase inhibitor. It is in clinical trial for treatment of several types of cancer.
gamma-secretase modulator 3
gamma-secretase modulator 3 is a γ-secretase inhibitor.
DBZ, also called dibenzazepine, is a γ-secretase inhibitor to treat Alzheimer′s Disease, and it also inhibit Notch signaling.
LY-411575 isomer 3, is an isomer of LY411575, which is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-based...
LY-411575, also known as LSN-411575, is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-basedγ-secretase ass...
PF-3084014, also called Nirogacestat, is a selective γ-secretase inhibitor (IC50= 6.2 nM in a cell-free assay) that was shown by the reduction of endogenous NIC...